Journal of pediatric hematology/oncology
-
J. Pediatr. Hematol. Oncol. · Jul 2010
Letter Case ReportsInadvertent intrathecal injection of PEG-asparaginase.
-
J. Pediatr. Hematol. Oncol. · May 2010
Case ReportsEarly diagnosis and treatment of cobalamin deficiency of infancy owing to occult maternal pernicious anemia.
We report case of an infant who presented with failure to thrive and developmental delay at 4 months of age. He was diagnosed to have vitamin B12 deficiency and antibodies to intrinsic factor secondary to undiagnosed maternal pernicious anemia. ⋯ We review the literature on this rare cause of cobalamin deficiency in infants. We highlight the factors determining the outcome and situations where raised index of suspicion could help in recognizing this preventable cause of developmental delay and learning difficulties.
-
J. Pediatr. Hematol. Oncol. · May 2010
Comment Letter Case ReportsRegarding "Intrathecal vincristine: 3 fatal cases and a review of the literature".
-
J. Pediatr. Hematol. Oncol. · Apr 2010
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Transplant-related problems have been partially overcome by using reduced-intensity conditioning (RIC), graft engineering, and alternative donors. In all, 21 leukemia patients with no suitable donor received a hematopoietic stem cell transplantation from a mismatched/haploidentical related (n=16) or unrelated donor (n=5). Fludarabine-RIC and PBSC graft were used. ⋯ CD3/CD19 depletion showed higher natural killer cell counts even after 1 year. Nonrelapse mortality (7% for matched CD34+-selected grafts and 11% for mismatched/haplo-CD3/CD19-depleted grafts), relapse probability (27% for related CD34+-selected patients and 33% for related CD3/CD19-depleted patients), and disease-free survival were similar for both the groups. In conclusion, using graft engineering procedures after RIC for hematopoietic stem cell transplantation offers a high probability of engraftment, fast immune recovery, and very low mortality even with mismatched donors.